MEEGHAN ESCOBAR: Open Payments
NPI 1548025364 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$913 in 53 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $135 · 2025 $913
Food & beverage: $913
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $117 |
| Lilly USA, LLC | 6 | $103 |
| GlaxoSmithKline, LLC. | 6 | $97 |
| ABBVIE INC. | 4 | $77 |
| Merck Sharp & Dohme LLC | 3 | $61 |
| Amgen Inc. | 4 | $59 |
| Novo Nordisk Inc | 3 | $50 |
| PFIZER INC. | 3 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
| Abbott Laboratories | 2 | $36 |
Products named: AIRSUPRA, MOUNJARO, SHINGRIX, GARDASIL 9, JARDIANCE, UBRELVY, CAPLYTA, FREESTYLE LIBRE 3.
Industry payments across AZ — which companies pay providers there.
